TY - JOUR
T1 - Beyond Primary HER2 Expression
T2 - Trastuzumab Deruxtecan’s Efficacy in Brain Metastasis
AU - Das, Glori
AU - Wong, Stephen T.C.
AU - Zhao, Hong
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/10
Y1 - 2024/10
N2 - This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in treating brain metastases from tumors originally classified as HER2-null or HER2-low, extending beyond its current use for breast cancer. This expanded application of T-DXd could provide new hope to patients dealing with challenging brain metastases, addressing an urgent need for effective treatment options.
AB - This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in treating brain metastases from tumors originally classified as HER2-null or HER2-low, extending beyond its current use for breast cancer. This expanded application of T-DXd could provide new hope to patients dealing with challenging brain metastases, addressing an urgent need for effective treatment options.
UR - http://www.scopus.com/inward/record.url?scp=85207675128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85207675128&partnerID=8YFLogxK
U2 - 10.3390/cancers16203525
DO - 10.3390/cancers16203525
M3 - Editorial
AN - SCOPUS:85207675128
SN - 2072-6694
VL - 16
JO - Cancers
JF - Cancers
IS - 20
M1 - 3525
ER -